Aspen has abandoned local lenacapavir production, citing no guaranteed demand, and is backing Merck’s alimatravir pill instead.
Local Lenacapavir Production: Aspen Exits, Eyes Alimatravir
Original Article by Tamar Kahn | Business Day | 4 September 2026
Aspen has abandoned local lenacapavir production, citing no guaranteed demand, and is backing Merck's alimatravir pill instead.
Image | Sukhina Marina | Adobe Stock/1611459282
More Posts
Discovery earnings growth strengthens
Discovery earnings growth accelerated as stronger cash generation, Discovery Bank and Vitality Health lifted performance.
Read more...
Childhood vaccination coverage data questioned
Childhood vaccination coverage estimates in South Africa are under scrutiny after questions emerged about the population figures used to calculate national immunisation rates. The National Department of Health said in late August that more than one-third of babies younger than one were completely unvaccinated. However, public health specialists in several provinces have questioned whether the […]
Read more...
Childhood vaccination rates under review
Uncertain population estimates may distort childhood vaccination rates. Health officials are reviewing the data and its implications.
Read more...